{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:31:07Z","timestamp":1794317467969,"version":"4.9.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ymgme.2023.107603","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T09:50:14Z","timestamp":1682761814000},"page":"107603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Global reach of over 20\u00a0years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community"],"prefix":"10.1016","volume":"139","author":[{"given":"Christoph","family":"Wanner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan T.","family":"Ebels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Maski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Politei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Banikazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o P.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.107603_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107603_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A case of \"angiokeratoma\"","volume":"10","author":"Anderson","year":"1898","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2023.107603_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01986897","article-title":"A contribution to the understanding of modular hemorrhagic purpura","volume":"43","author":"Fabry","year":"1898","journal-title":"Arch. Dermatol. Syphilis"},{"issue":"9","key":"10.1016\/j.ymgme.2023.107603_bb0020","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry\u2019s disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid","volume":"238","author":"Sweeley","year":"1963","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107603_bb0025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107603_bb0030","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"13","key":"10.1016\/j.ymgme.2023.107603_bb0035","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1073\/pnas.83.13.4859","article-title":"Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme","volume":"83","author":"Bishop","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2023.107603_bb0040","first-page":"30","article-title":"The gene encoding alpha-galactosidase A and gene rearrangements causing Fabry disease","volume":"102","author":"Kornreich","year":"1989","journal-title":"Trans. Assoc. Am. Phys."},{"key":"10.1016\/j.ymgme.2023.107603_bb0055","series-title":"Fabrazyme Summary of Product Characteristics. Genzyme Europe B.V., Amsterdam, The Netherlands","year":"2021"},{"key":"10.1016\/j.ymgme.2023.107603_bb0060","series-title":"Replagal Summary of Product Characteristics. Shire Human Genetic Therapies A.B., Stockholm, Sweden","year":"2021"},{"key":"10.1016\/j.ymgme.2023.107603_bb0065","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4 (7)","author":"Desnick","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2023.107603_bb0070","series-title":"Galafold Summary of Product Characteristics. Amicus Therapeutics Europe Limited, Dublin, Ireland","year":"2021"},{"issue":"4","key":"10.1016\/j.ymgme.2023.107603_bb0075","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107603_bb0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107603_bb0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107603_bb0090","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107603_bb0095","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107603_bb0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107603_bb0105","first-page":"145","article-title":"Fabry's disease: new concepts about its natural history, evolution and treatment, in relation to the findings of the Fabry Registry","volume":"29","author":"Politei","year":"2009","journal-title":"Rev. Nefrol. Di\u00e1l. Transpl."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0110","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.ymgme.2023.107603_bb0115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","article-title":"A validated disease severity scoring system for Fabry disease","volume":"99","author":"Giannini","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107603_bb0130","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107603_bb0135","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107603_bb0140","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease: natural history data from the Fabry Registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0145","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107603_bb0155","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107603_bb0160","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4238\/2013.January.24.5","article-title":"Demographic characterization of Brazilian patients enrolled in the Fabry Registry","volume":"12","author":"Martins","year":"2013","journal-title":"Genet. Mol. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107603_bb0165","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ijcp.12081","article-title":"Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry","volume":"67","author":"Politei","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ymgme.2023.107603_bb0170","first-page":"91","article-title":"Fabry disease in Latin America: data from the Fabry Registry","volume":"8","author":"Villalobos","year":"2013","journal-title":"JIMD Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107603_bb0175","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107603_bb0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","article-title":"Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry Registry","volume":"119","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107603_bb0185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107603_bb0190","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107603_bb0195","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol. Genet. Genomic Med."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107603_bb0200","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107603_bb0205","first-page":"45","article-title":"Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta: data from the Fabry Registry","volume":"38","author":"Wilcox","year":"2018","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107603_bb0210","first-page":"107","article-title":"The clinical profiles of female patients with Fabry disease in Latin America: a Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status","volume":"49","author":"Martins","year":"2019","journal-title":"JIMD Rep."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107603_bb0215","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup","volume":"57","author":"Germain","year":"2020","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2023.107603_bb0220","article-title":"Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: a Fabry Registry analysis stratified by phenotype","volume":"25","author":"Hopkin","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0225","first-page":"825","article-title":"Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis, E.S.C","volume":"7","author":"Wanner","year":"2020","journal-title":"Heart Fail."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107603_bb0230","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/fca-2022-0047","article-title":"Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment","volume":"18","author":"Wanner","year":"2022","journal-title":"Future Cardiol."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107603_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106967","article-title":"Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry Registry","volume":"138","author":"Hopkin","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107603_bb0240","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cge.14102","article-title":"Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease","volume":"101","author":"Germain","year":"2022","journal-title":"Clin. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107603_bb0245","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/biom11070951","article-title":"Newborn screening for Fabry disease in northeastern Italy: results of five years of experience","volume":"11","author":"Gragnaniello","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymgme.2023.107603_bb0250","series-title":"Neurometabolic Hereditary Diseases of Adults: Diagnosis and Treatment","article-title":"Principles of human genetics and Mendelian inheritance","author":"Germain","year":"2018"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107603_bb0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107603_bb0260","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/biom11020271","article-title":"Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions","volume":"11","author":"Kok","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107603_bb0265","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13023-022-02517-0","article-title":"Rare lysosomal disease registries: lessons learned over three decades of real-world evidence","volume":"17","author":"Mistry","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107603_bb0275","series-title":"Fabrazyme US Prescribing Information","year":"2021"},{"issue":"6","key":"10.1016\/j.ymgme.2023.107603_bb0280","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.7326\/0003-4819-63-6-1059","article-title":"Fabry\u2019s disease (angiokeratoma corporis diffusum): case report on a rare disease","volume":"63","author":"Dempsey","year":"1965","journal-title":"Ann. Intern. Med."},{"issue":"21","key":"10.1016\/j.ymgme.2023.107603_bb0285","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for Fabry disease","volume":"284","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2023.107603_bb0290","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0002-9343(59)90200-1","article-title":"Fabry\u2019s disease (angiokeratoma corporis diffusum universale). An unusual syndrome with multisystem involvement and unique skin manifestations","volume":"27","author":"Karr","year":"1959","journal-title":"Am. J. Med."},{"issue":"122","key":"10.1016\/j.ymgme.2023.107603_bb0295","first-page":"177","article-title":"Angiokeratoma corporis diffusum: a study of eight affected families","volume":"31","author":"Wise","year":"1962","journal-title":"Q. J. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107603_bb0300","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000254765","article-title":"Angiokeratoma corporis diffusum Fabry","volume":"128","author":"De Groot","year":"1964","journal-title":"Dermatologica"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107603_bb0305","first-page":"67","article-title":"Angiokeratoma corporis diffusum--Fabry's disease","volume":"34","author":"Colombi","year":"1967","journal-title":"Helv. Med. Acta"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107603_bb0315","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/archopht.1979.01020010327008","article-title":"The ocular manifestations in Fabry's disease","volume":"97","author":"Sher","year":"1979","journal-title":"Arch. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0320","first-page":"246","article-title":"Gastrointestinal structure and function in Fabry's disease","volume":"76","author":"Sheth","year":"1981","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107603_bb0325","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.32.5.498","article-title":"Fabry disease: impaired autonomic function","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"issue":"277","key":"10.1016\/j.ymgme.2023.107603_bb0330","first-page":"491","article-title":"The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients","volume":"75","author":"Morgan","year":"1990","journal-title":"Q. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0335","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1525-1470.1995.tb00161.x","article-title":"Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease","volume":"12","author":"Shelley","year":"1995","journal-title":"Pediatr. Dermatol."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107603_bb0340","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107603_bb0345","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2023.107603_bb0350","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1023\/A:1012499119196","article-title":"Natural history of Fabry disease in males: preliminary observations","volume":"24","author":"Schiffmann","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.107603_bb0355","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000060184","article-title":"Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy","volume":"136","author":"Desnick","year":"2001","journal-title":"Contrib. Nephrol."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107603_bb0360","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","article-title":"Arrhythmia and clinical cardiac findings in children with Anderson-Fabry disease","volume":"120","author":"Wilson","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107603_bb0365","doi-asserted-by":"crossref","first-page":"107538","DOI":"10.1016\/j.ymgme.2023.107538","article-title":"Prevalence of lymphedema among Anderson-Fabry disease patients: a report from the Fabry Registry","volume":"138","author":"Alkhatib","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"13","key":"10.1016\/j.ymgme.2023.107603_bb0370","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2174\/0929867324666170616102112","article-title":"Biomarkers for diagnosing and staging of Fabry disease","volume":"25","author":"Kramer","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107603_bb0375","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/ckj\/sfaa227","article-title":"Fabry disease and COVID-19: international expert recommendations for management based on real-world experience","volume":"13","author":"Laney","year":"2020","journal-title":"Clin. Kidney J."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107603_bb0380","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/joim.12186","article-title":"Use of self-controlled designs in pharmacoepidemiology","volume":"275","author":"Hallas","year":"2014","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107603_bb0385","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","article-title":"Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry","volume":"17","author":"Beck","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107603_bb0390","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107603_bb0395","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Feldt-Rasmussen","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107603_bb0400","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223002330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223002330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:54:12Z","timestamp":1761090852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223002330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1096719223002330"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107603","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global reach of over 20\u00a0years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107603"}}